IOVA241108C9000
- 2.65
- +0.25+10.42%
Iovance Biotherapeutics Newsroom
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
Promising Efficacy and Long-term Response of Iovance Biotherapeutics' Lifileucel in NSCLC: A Buy Recommendation
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (NASDAQ:IOVA) Delivers Shareholders Solid 166% Return Over 1 Year, Surging 4.9% in the Last Week Alone
Earnings Preview: IOVA to Report Financial Results Post-market on November 07
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Why Iovance Biotherapeutics Stock Triumphed on Thursday
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
UBS Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $17
Iovance Biotherapeutics Initiated With a Buy at UBS
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc
Iovance Biotherapeutics Call Volume Above Normal and Directionally Bullish
Piper Sandler Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating, Maintains Target Price $10
Piper Sandler Reaffirms Their Hold Rating on Iovance Biotherapeutics (IOVA)
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy?
Bullish Iovance Biotherapeutics Insiders Loaded Up On US$48.3m Of Stock
Iovance Biotherapeutics (NASDAQ:IOVA) Delivers Shareholders Favorable 74% Return Over 1 Year, Surging 4.9% in the Last Week Alone
3 Things You Need to Know If You Buy Iovance Biotherapeutics Today